AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03380364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hystroscope
Description: Procedure: Hysteroscopy Office hysteroscopy will be performed during the proliferative phaseof the menstrual cycle.~All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.~Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection.~Other Name: ROH: Routine Office Hysteroscopy Device: Hysteroscope The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 5-mm diameter diagnostic rigid sheath with an atraumatic tip (Karl Storz Endoscopy).~Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg
Study NCT03357978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bioelectrical impedance analysis
Description: Electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
Study NCT03357978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood draw
Description: Blood samples are taken from sober patients
Study NCT03357978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: transient elastography (FibroScan)
Description: FibroScan is a noninvasive tool to measure liver stiffness as an indication of fatty liver and liver fibrosis using ultrasound
Study NCT03357978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ataxia score
Description: Klockgether ataxia score ranges from 0 to 35 points in which 0 means no symptoms and 35 stands for final stage of disease. It includes seven ataxia associated symptoms: dysarthria, intention tremor, ataxia of gait, stance, dysdiadochokinesia, upper limb and lower limb
Study NCT03357978 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Five-Times-Sit-to-Stand Test
Description: The test measures the complete time which is necessary for an individual to stand up and sit down on a chair five times in series
Study NCT03974698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemiarthroplasty
Description: Radiological features comparing the femoral stem position is measured on the postoperative x-ray. Presence of heterotopic ossification is assessed on the 12 months follow up.
Study NCT03112447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: absorbable cartilage nail
Description: The experiment group patients were fixed with absorbable cartilage nails
Study NCT03112447 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional Kirschner wires
Description: The control group were fixed with traditional Kirschner wires
Study NCT03379558 — intervention group
Intervention type: DRUG
Intervention: ALIROCUMAB SAR236553 (REGN727)
Description: Pharmaceutical form:as per routine practice Route of administration: subcutaneous
Study NCT00436956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (DCE-MRI)
Description: Scans evaluate tumor tissue and blood flow.
Study NCT00436956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: 20 mg oral daily for 28 days
Study NCT00436956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10mg orally daily in combination with AZD2171 20mg daily.
Study NCT03650673 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Identification of subgroups of patients with early AD with risk of progression
Description: Clinical examination with questionnaires, Biological collection, Imaging (radiography, densitometry, ultrasound, and MRI)
Study NCT03751436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO
Study NCT03751436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT00858715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100 mg aspirin
Study NCT00858715 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 75 mg (Arm 1) and 150 mg (Arm 2)
Study NCT02454634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH1 peptide vaccine
Study NCT02200991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIXISENATIDE AVE0010
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02200991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Pharmaceutical form:tablet Route of administration: oral
Study NCT02200991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02200991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine HOE901
Description: Pharmaceutical form:solution Route of administration: subcutaneous
Study NCT02525302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-100
Description: HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
Study NCT02854605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9674
Description: Tablet administered orally once daily
Study NCT02854605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GS-9674
Description: Tablet(s) administered orally once daily
Study NCT02854605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match GS-9674
Description: Tablet(s) administered orally once daily
Study NCT01678599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Benznidazole
Description: All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients > 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
Study NCT03268018 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser induced pressure wave calcium modification
Description: A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
Study NCT01299415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadimezan™
Study NCT01451554 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: portion control plate
Description: Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
Study NCT01451554 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: self-help booklets
Study NCT00607997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vosaroxin
Description: Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
Study NCT03247361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity IMT + Aerobic/resistance exercise
Description: High-intensity IMT
Study NCT03247361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity IMT + Aerobic/resistance exercise
Description: Low-intensity IMT
Study NCT03247361 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IMT + Aerobic/resistance exercise
Description: Aerobic and resistance exercise
Study NCT05940077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Community-based exercise involving non-contact boxing and individualized balance training
Study NCT00248833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Description: The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 25µg with and without adjuvant were administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
Study NCT00248833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Description: The study was conducted as a phase 1, outpatient, dose-escalating study for the Meningococcal 44/76 MOS NOMV 5D Vaccine (lot number 1119). 50µg without adjuvant was administered. Vaccinations were given intramuscularly at 0, 6, and 24 weeks.
Study NCT03605849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centanafadine SR
Description: 200mg, BID, oral tablets
Study NCT01353573 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Gantry Radiosurgery
Description: Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
Study NCT01353573 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Robotic Radiosurgery
Description: Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
Study NCT01329432 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Take care
Description: In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
Study NCT01329432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: InSurE
Description: infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
Study NCT02368210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 122-0551 Foam
Description: Topical Foam
Study NCT02368210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical Foam
Study NCT02240303 — intervention group
Intervention type: PROCEDURE
Intervention: Quantitative Sensory Testing (QST)
Description: Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
Study NCT02240303 — intervention group
Intervention type: PROCEDURE
Intervention: Physical Performance
Description: Participants in both groups will have a Physical Performance test.
Study NCT02240303 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants in both groups will have an magnetic resonance imaging (MRI).
Study NCT02240303 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sample
Description: Participants in both groups will have blood samples taken.
Study NCT03418194 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcutaneous acupoint electrical stimulation
Description: Transcutaneous acupoint electrical stimulation(TAES) is a kind of noninvasive therapy similar to acupuncture and moxibustion. Its physiological effect is similar to that of electroacupuncture and hand acupuncture which is a Chinese traditonal therapy using acupuncture.
Study NCT03418194 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham transcutaneous acupoint electrical stimulation
Description: Sham transcutaneous acupoint electrical stimulation is the same procedure as transcutaneous acupoint electrical stimulation at points without electronic stimulation.
Study NCT04620694 — intervention group
Intervention type: DEVICE
Intervention: Choice of arterial cannulation site at the beginning of the surgery
Description: Choice of arterial cannulation site at the beginning of the surgery is at the discretion of the anesthesia physician.
Study NCT00461110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663513
Description: mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
Study NCT04387799 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serology for Covid-19
Description: Antibody tests designed to provide results to individuals or healthcare providers can show whether someone was previously infected with SARS-CoV-2 being the RT-PCR negative for the population of patients
Study NCT00694720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE0657
Description: capsules once a day at bedtime
Study NCT03827850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERDAFITINIB
Description: Daily in a range from 3 mg to 9 mg
Study NCT03842631 — intervention group
Intervention type: DRUG
Intervention: Timolol Maleate 0.5% Oph Soln
Description: External use of 0.5% Timolol Maleate Drops for all patients in different depths of IH lesion.
Study NCT01125462 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Questionnaire (FertiQoL)
Description: Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
Study NCT01841112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received matching placebo to the BI-409306 (film-coated tablet/s), administered orally on day 1 for single dose (SD) segment and on day 3 to day 9 for multiple dose (MD) segment
Study NCT01841112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 25 milligram (mg) SD
Description: Subjects received 25 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
Study NCT01841112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 50 mg SD
Description: Subjects received 50 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
Study NCT01841112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 100 mg SD
Description: Subjects received 100 mg single dose of BI-409306 (film-coated tablet/s), administered orally once on day 1
Study NCT01841112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-409306 100 mg MD
Description: Subjects received 100 mg multiple dose of BI-409306 (film-coated tablet/s), administered orally once on day 3 to day 9
Study NCT05168137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose colchicine
Description: prescribed colchicine 0.6 mg/day
Study NCT05168137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of colchicine
Study NCT04114812 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended learning
Description: In the intervention group, students will be given access to an e-learning platform that contains five e-learning modules. They will attend individual small group tutoring sessions, with a maximum of 4 students per group. They will be able to book these sessions at a dedicated web platform. They will have 16 weeks in which to complete the 5 e-learning modules and 16 hours of practical training. Progress will be monitored and supported by regular follow-up messages and calls by the study team. Students must hand in the logbook with tutors' signatures when they enter the exam. All students within the blended learning group that completed 5 hours of e-learning as well as 16 hours of peer-tutoring and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
Study NCT04114812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard course
Description: In the standard course or control group, students will participate in a 2.5-day course in abdominal ultrasound, comprising 5 hours of lectures and 16 hours of ultrasound training in small groups, with a maximum of 4 students per group. The course will be held in an ultrasound training centre in Bern. All students within the standard course group that participated in the whole 2.5 day course and passed a predefined total score in the test directly after the intervention will receive a course certificate. Students not fulfilling all of these criteria will have the possibility to complete the program and/or re-do the test after the end of the study.
Study NCT03467698 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Real stimulation
Study NCT03467698 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham stimulation
Study NCT02927652 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.~If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed.
Study NCT00623363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: piclozotan
Description: piclozotan, intravenous (IV) infusion
Study NCT00623363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride (normal saline)
Description: 0.9% sodium chloride (normal saline) intravenous (IV) infusion
Study NCT02562144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylocaine spray
Description: Cutaneous xylocaine spray before intravenous cannulation.
Study NCT02562144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cutaneous placebo before intravenous cannulation.
Study NCT04114097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betnovate, betamethasone dipropionate ointment 0.1% and placebo
Description: Explore the systemic effects of Betnovate
Study NCT04114097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic, tacrolimus ointment 0.1%
Description: Compare the systemic effects of Betnovate to Protopic
Study NCT01138761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse instruction
Description: The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group.
Study NCT02584036 — intervention group
Intervention type: BIOLOGICAL
Intervention: Vaccine administration by a pharmacist
Description: Administration, number and types, of vaccine(s) by a pharmacist
Study NCT02584036 — intervention group
Intervention type: BEHAVIORAL
Intervention: Unmet vaccination needs identified and met
Description: Identification of unmet vaccination needs and having those needs met
Study NCT02584036 — intervention group
Intervention type: BEHAVIORAL
Intervention: Vaccination forecast review and patient education
Description: Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
Study NCT04706793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to 52 weeks
Study NCT04706793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Etrasimod matching placebo tablet by mouth, once daily up to 52 weeks
Study NCT00409591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maternal and infant nevirapine
Description: * In women, one NVP 200 mg tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately
Study NCT00409591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maternal placebo and infant nevirapine
Description: * In women, one placebo tablet at onset of labor;~* In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours~Comparison between Arms 1 and 2 is double-blinded.
Study NCT00409591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maternal lopinavir+ritonavir
Description: - In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
Study NCT00409591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zidovudine
Description: In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
Study NCT00409591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zidovudine
Description: In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
Study NCT00592462 — intervention group
Intervention type: PROCEDURE
Intervention: Whole Body MRI
Description: The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
Study NCT00839332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2603618
Study NCT00839332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine